Morphine preconditioning confers cardioprotection in doxorubicin-induced failing rat hearts via ERK/GSK-3β pathway independent of PI3K/Akt

Toxicology and Applied Pharmacology

Volumn 288, Issue 3, 2015, Pages 349-358

  He, Shu Fang ^a   Jin, Shi Yun ^a   Wu, Hao ^a   Wang, Bin ^a   Wu, Yun Xiang ^a   Zhang, Shu Jie ^a   Irwin, Michael G ^b   Wong, Tak Ming ^b   Zhang, Ye ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Cardioprotection; Doxorubicin; Heart failure; Ischemia reperfusion injury; Morphine preconditioning; Signal pathways

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; DOXORUBICIN; GLYCOGEN SYNTHASE KINASE 3BETA; LACTATE DEHYDROGENASE; MITOGEN ACTIVATED PROTEIN KINASE; MORPHINE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; WORTMANNIN; CARDIOTONIC AGENT; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA;

ADULT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; HEART FAILURE; HEART INFARCTION PREVENTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; ISCHEMIC PRECONDITIONING; ISOLATED HEART; M MODE ECHOCARDIOGRAPHY; MALE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PROTEIN EXPRESSION; RAT; REPERFUSION INJURY; SIGNAL TRANSDUCTION; ANIMAL; DRUG EFFECTS; GENETICS; HEART; METABOLISM; PATHOLOGY; PHOSPHORYLATION; SPRAGUE DAWLEY RAT;

ANIMALS; CARDIOTONIC AGENTS; DOXORUBICIN; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GLYCOGEN SYNTHASE KINASE 3; HEART; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MALE; MORPHINE; MYOCARDIAL REPERFUSION INJURY; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION;

EID: 84943664581     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2015.08.007     Document Type: Article

References (49)

1. Andersen A., Povlsen J.A., Botker H.E., Nielsen-Kudsk J.E. Right ventricular hypertrophy and failure abolish cardioprotection by ischaemic pre-conditioning. Eur. J. Heart Fail. 2013, 15(11):1208-1214.
2. Balakumar P., Singh H., Singh M., Anand-Srivastava M. The impairment of preconditioning-mediated cardioprotection in pathological conditions. Pharmacol. Res. 2009, 60(1):18-23.
3. Belcheva M.M., Szucs M., Wang D., Sadee W., Coscia C.J. mu-Opioid receptor-mediated ERK activation involves calmodulin-dependent epidermal growth factor receptor transactivation. J. Biol. Chem. 2001, 276(36):33847-33853.
4. Carll A.P., Willis M.S., Lust R.M., Costa D.L., Farraj A.K. Merits of non-invasive rat models of left ventricular heart failure. Cardiovasc. Toxicol. 2011, 11(2):91-112.
5. Chen X., Chen Y., Bi Y., Fu N., Shan C., Wang S., et al. Preventive cardioprotection of erythropoietin against doxorubicin-induced cardiomyopathy. Cardiovasc. Drugs Ther. 2007, 21(5):367-374.
6. Chen Q.L., Gu E.W., Zhang L., Cao Y.Y., Zhu Y., Fang W.P. Diabetes mellitus abrogates the cardioprotection of sufentanil against ischaemia/reperfusion injury by altering glycogen synthase kinase-3beta. Acta Anaesthesiol. Scand. 2012, 57(2):236-242.
7. Cohen M.V., Philipp S., Krieg T., Cui L., Kuno A., Solodushko V., et al. Preconditioning-mimetics bradykinin and DADLE activate PI3-kinase through divergent pathways. J. Mol. Cell. Cardiol. 2007, 42(4):842-851.
8. Croteau E., Gascon S., Bentourkia M., Langlois R., Rousseau J.A., Lecomte R., et al. [11C]Acetate rest-stress protocol to assess myocardial perfusion and oxygen consumption reserve in a model of congestive heart failure in rats. Nucl. Med. Biol. 2012, 39(2):287-294.
9. Ferdinandy P., Schulz R., Baxter G.F. Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacol. Rev. 2007, 59(4):418-458.
10. Fryer R.M., Pratt P.F., Hsu A.K., Gross G.J. Differential activation of extracellular signal regulated kinase isoforms in preconditioning and opioid-induced cardioprotection. J. Pharmacol. Exp. Ther. 2001, 296(2):642-649.
11. Fryer R.M., Wang Y., Hsu A.K., Gross G.J. Essential activation of PKC-delta in opioid-initiated cardioprotection. Am. J. Physiol. Heart Circ. Physiol. 2001, 280(3):H1346-H1353.
12. Gaasch W.H., Zile M.R., Hoshino P.K., Weinberg E.O., Rhodes D.R., Apstein C.S. Tolerance of the hypertrophic heart to ischemia. Studies in compensated and failing dog hearts with pressure overload hypertrophy. Circulation 1990, 81(5):1644-1653.
13. Gross E.R., Hsu A.K., Gross G.J. Opioid-induced cardioprotection occurs via glycogen synthase kinase beta inhibition during reperfusion in intact rat hearts. Circ. Res. 2004, 94(7):960-966.
14. Gross E., Hsu A., Gross G. The JAK/STAT pathway is essential for opioid-induced cardioprotection: JAK2 as a mediator of STAT3, Akt, and GSK-3 beta. Am. J. Physiol. Heart Circ. Physiol. 2006, 291(2):H827-H834.
15. Gross E.R., Hsu A.K., Gross G.J. Diabetes abolishes morphine-induced cardioprotection via multiple pathways upstream of glycogen synthase kinase-3beta. Diabetes 2007, 56(1):127-136.
16. Gross E.R., Hsu A.K., Gross G.J. GSK3beta inhibition and K(ATP) channel opening mediate acute opioid-induced cardioprotection at reperfusion. Basic Res. Cardiol. 2007, 102(4):341-349.
17. Hausenloy D.J., Tsang A., Mocanu M.M., Yellon D.M. Ischemic preconditioning protects by activating prosurvival kinases at reperfusion. Am. J. Physiol. Heart Circ. Physiol. 2005, 288(2):H971-H976.
18. Hausenloy D.J., Boston-Griffiths E., Yellon D.M. Cardioprotection during cardiac surgery. Cardiovasc. Res. 2012, 94(2):253-265.
19. Hayward R., Hydock D.S. Doxorubicin cardiotoxicity in the rat: an in vivo characterization. J. Am. Assoc. Lab. Anim. Sci. 2007, 46(4):20-32.
20. Herman E.H., Zhang J., Lipshultz S.E., Rifai N., Chadwick D., Takeda K., et al. Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin. J. Clin. Oncol. 1999, 17(7):2237-2243.
21. Houser S.R., Margulies K.B., Murphy A.M., Spinale F.G., Francis G.S., Prabhu S.D., et al. Animal models of heart failure: a scientific statement from the American Heart Association. Circ. Res. 2012, 111(1):131-150.
22. Huh J., Gross G.J., Nagase H., Liang B.T. Protection of cardiac myocytes via delta(1)-opioid receptors, protein kinase C, and mitochondrial K(ATP) channels. Am. J. Physiol. Heart Circ. Physiol. 2001, 280(1):H377-H383.
23. Juhaszova M., Zorov D.B., Yaniv Y., Nuss H.B., Wang S., Sollott S.J. Role of glycogen synthase kinase-3beta in cardioprotection. Circ. Res. 2009, 104(11):1240-1252.
24. Kilkenny C., Browne W., Cuthill I.C., Emerson M., Altman D.G., Group NCRRGW Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br. J. Pharmacol. 2010, 160(7):1577-1579.
25. Kim H.S., Cho J.E., Hwang K.C., Shim Y.H., Lee J.H., Kwak Y.L. Diabetes mellitus mitigates cardioprotective effects of remifentanil preconditioning in ischemia-reperfused rat heart in association with anti-apoptotic pathways of survival. Eur. J. Pharmacol. 2010, 628(1-3):132-139.
26. Kozluca O., Olcay E., Surucu S., Guran Z., Kulaksiz T., Uskent N. Prevention of doxorubicin induced cardiotoxicity by catechin. Cancer Lett. 1996, 99(1):1-6.
27. Li R., Wong G.T., Wong T.M., Zhang Y., Xia Z., Irwin M.G. Intrathecal morphine preconditioning induces cardioprotection via activation of delta, kappa, and mu opioid receptors in rats. Anesth. Analg. 2009, 108(1):23-29.
28. Li L., Zhang H., Li T., Zhang B. Involvement of adenosine monophosphate-activated protein kinase in morphine-induced cardioprotection. J. Surg. Res. 2011, 169(2):179-187.
29. Liu X., Gu X., Li Z., Li X., Li H., Chang J., et al. Neuregulin-1/erbB-activation improves cardiac function and survival in models of ischemic, dilated, and viral cardiomyopathy. J. Am. Coll. Cardiol. 2006, 48(7):1438-1447.
30. Lu L., Wu W., Yan J., Li X., Yu H., Yu X. Adriamycin-induced autophagic cardiomyocyte death plays a pathogenic role in a rat model of heart failure. Int. J. Cardiol. 2009, 134(1):82-90.
31. Ma L.L., Ge H.W., Kong F.J., Qian L.B., Hu B.C., Li Q., et al. Ventricular hypertrophy abrogates intralipid-induced cardioprotection by alteration of reperfusion injury salvage kinase/glycogen synthase kinase-3 beta signal. Shock 2014, 41(5):435-442.
32. Matsui H., Morishima I., Numaguchi Y., Toki Y., Okumura K., Hayakawa T. Protective effects of carvedilol against doxorubicin-induced cardiomyopathy in rats. Life Sci. 1999, 65(12):1265-1274.
33. Miki T., Miura T., Tsuchida A., Nakano A., Hasegawa T., Fukuma T., et al. Cardioprotective mechanism of ischemic preconditioning is impaired by postinfarct ventricular remodeling Th. Circulation 2000, 102(4):458-463.
34. Miki T., Miura T., Yano T., Takahashi A., Sakamoto J., Tanno M., et al. Alteration in erythropoietin-induced cardioprotective signaling by postinfarct ventricular remodeling. J. Pharmacol. Exp. Ther. 2006, 317(1):68-75.
35. Miki T., Miura T., Tanno M., Nishihara M., Naitoh K., Sato T., et al. Impairment of cardioprotective PI3K-Akt signaling by post-infarct ventricular remodeling is compensated by an ERK-mediated pathway. Basic Res. Cardiol. 2007, 102(2):163-170.
36. Patane S. A challenge in cardiology: the oncosurgery. Int. J. Cardiol. 2014, 174(2):411-412.
37. Peart J.N., Gross E.R., Gross G.J. Opioid-induced preconditioning: recent advances and future perspectives. Vasc. Pharmacol. 2005, 42(5-6):211-218.
38. Qi J.S., Kam K.W., Chen M., Wu S., Wong T.M. Failure to confer cardioprotection and to increase the expression of heat-shock protein 70 by preconditioning with a kappa-opioid receptor agonist during ischaemia and reperfusion in streptozotocin-induced diabetic rats. Diabetologia 2004, 47(2):214-220.
39. Schultz J.E., Gross G.J. Opioids and cardioprotection. Pharmacol. Ther. 2001, 89(2):123-137.
40. Suleman N., Somers S., Smith R., Opie L.H., Lecour S.C. Dual activation of STAT-3 and Akt is required during the trigger phase of ischaemic preconditioning. Cardiovasc. Res. 2008, 79(1):127-133.
41. Tegeder I., Geisslinger G. Opioids as modulators of cell death and survival-unraveling mechanisms and revealing new indications. Pharmacol. Rev. 2004, 56(3):351-369.
42. Tong H., Imahashi K., Steenbergen C., Murphy E. Phosphorylation of glycogen synthase kinase-3beta during preconditioning through a phosphatidylinositol-3-kinase-dependent pathway is cardioprotective. Circ. Res. 2002, 90(4):377-379.
43. Ueno M., Kakinuma Y., Yuhki K., Murakoshi N., Iemitsu M., Miyauchi T., et al. Doxorubicin induces apoptosis by activation of caspase-3 in cultured cardiomyocytes in vitro and rat cardiac ventricles in vivo. J. Pharmacol. Sci. 2006, 101(2):151-158.
44. van Waes J.A., Nathoe H.M., de Graaff J.C., Kemperman H., de Borst G.J., Peelen L.M., et al. Myocardial injury after noncardiac surgery and its association with short-term mortality. Circulation 2013, 127(23):2264-2271.
45. Vigneron F., Dos Santos P., Lemoine S., Bonnet M., Tariosse L., Couffinhal T., et al. GSK-3beta at the crossroads in the signalling of heart preconditioning: implication of mTOR and Wnt pathways. Cardiovasc. Res. 2011, 90(1):49-56.
46. Whittington H.J., Harding I., Stephenson C.I., Bell R., Hausenloy D.J., Mocanu M.M., et al. Cardioprotection in the aging, diabetic heart: the loss of protective Akt signalling. Cardiovasc. Res. 2013, 99(4):694-704.
47. Xi J., Tian W., Zhang L., Jin Y., Xu Z. Morphine prevents the mitochondrial permeability transition pore opening through NO/cGMP/PKG/Zn2+/GSK-3beta signal pathway in cardiomyocytes. Am. J. Physiol. Heart Circ. Physiol. 2009, 298(2):H601-H607.
48. Xu J., Tian W., Ma X., Guo J., Shi Q., Jin Y., et al. The molecular mechanism underlying morphine-induced Akt activation: roles of protein phosphatases and reactive oxygen species. Cell Biochem. Biophys. 2011, 61(2):303-311.
49. Zhang Y., Irwin M.G., Wong T.M., Chen M., Cao C.M. Remifentanil preconditioning confers cardioprotection via cardiac kappa- and delta-opioid receptors. Anesthesiology 2005, 102(2):371-378.